Piper Jaffray Starts Genocea Biosciences (GNCA) at Overweight
Get Alerts GNCA Hot Sheet
Rating Summary:
9 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Piper Jaffray initiates coverage on Genocea Biosciences (NASDAQ: GNCA) with a Overweight rating and a price target of $14.00.
Analyst Edward Tenthoff commented, "Genocea is a next generation vaccine company developing candidates that elicit a T-cell response versus B-cell immunity of traditional vaccines. Genocea will report Phase II data from its two lead vaccines this year. GEN-003 is a therapeutic vaccine for genital herpes targeting HSV-2 with top-line data from a 310-patient Phase II trial in late 2Q:15. GEN-004 is a prophylactic vaccine for pneumococcus with data from a 90-patient Phase II "challenge" study in 4Q:15. GEN-004 could be a universal vaccine that improves on Pfizer's blockbuster Prevnar13. We expect clinical data this year to drive value and position Genocea as a potential acquisition target by a larger vaccine player."
For an analyst ratings summary and ratings history on Genocea Biosciences click here. For more ratings news on Genocea Biosciences click here.
Shares of Genocea Biosciences closed at $9.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loop Capital Starts DoorDash Inc. (DASH) at Buy, 'Category Killer with Stellar Execution'
- QuantumScape (QS) PT Lowered to $6 at Truist Securities
- Yageo Corp. (2327:TT) (YAGOY) PT Lowered to NT$656 at HSBC
Create E-mail Alert Related Categories
Analyst Comments, Hot New Coverage, New CoverageRelated Entities
Piper Jaffray, Definitive Agreement, Edward TenthoffSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!